Drug discrimination
| Animal testing |
|---|
 |
| Main articles |
| Testing on |
| Issues |
| Cases |
| Companies |
| Groups/campaigns |
|
| Writers/activists |
| Categories |
Drug discrimination (DD) is a technique in behavioral neuroscience used to evaluate the discriminative stimulus properties of psychoactive drugs.[1][2][3][4] The discriminative stimulus properties of drugs are believed to reflect their subjective effects.[1] When partial or full stimulus generalization of a test drug to a training drug occurs, the test drug can be assumed to have effects that are subjectively similar to those of the training drug.[2] Drug discrimination tests are usually performed in animals, but have also been conducted in humans.[5][6] Drug discrimination assays have been employed to assess whether drugs have hallucinogen- or entactogen-like effects, among many other types of drug effects.[7][8][9]
References
[edit]- ^ a b Porter JH, Prus AJ, Overton DA (2018). "Drug Discrimination: Historical Origins, Important Concepts, and Principles". Curr Top Behav Neurosci. 39: 3–26. doi:10.1007/7854_2018_40. PMID 29637526.
- ^ a b Young, Richard (2009). "Drug Discrimination". Methods of Behavior Analysis in Neuroscience. Boca Raton (FL): CRC Press/Taylor & Francis. PMID 21204332. Retrieved 1 November 2024.
- ^ Colpaert FC (October 1999). "Drug discrimination in neurobiology". Pharmacol Biochem Behav. 64 (2): 337–345. doi:10.1016/s0091-3057(99)00047-7. PMID 10515310.
- ^ Stolerman, I.P. (1993). "Drug discrimination". Techniques in the Behavioral and Neural Sciences. Elsevier. p. 217–243. doi:10.1016/b978-0-444-81444-9.50014-6. ISSN 0921-0709.
- ^ Bolin BL, Alcorn JL, Reynolds AR, Lile JA, Rush CR (August 2016). "Human drug discrimination: A primer and methodological review". Exp Clin Psychopharmacol. 24 (4): 214–228. doi:10.1037/pha0000077. PMC 4965187. PMID 27454673.
- ^ Bolin BL, Alcorn JL, Reynolds AR, Lile JA, Stoops WW, Rush CR (2018). "Human Drug Discrimination: Elucidating the Neuropharmacology of Commonly Abused Illicit Drugs". Curr Top Behav Neurosci. 39: 261–295. doi:10.1007/7854_2016_10. PMC 5461212. PMID 27272070.
- ^ Baker LE (2018). "Hallucinogens in Drug Discrimination". Curr Top Behav Neurosci. 36: 201–219. doi:10.1007/7854_2017_476. PMID 28484970.
- ^ Winter JC (April 2009). "Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines". Psychopharmacology (Berl). 203 (2): 251–263. doi:10.1007/s00213-008-1356-8. PMID 18979087.
- ^ Mori T, Suzuki T (2018). "The Discriminative Stimulus Properties of Hallucinogenic and Dissociative Anesthetic Drugs". Curr Top Behav Neurosci. 39: 141–152. doi:10.1007/7854_2016_29. PMID 27586539.
Further reading
[edit]- Glennon, R.A.; Young, R. (2011). Drug Discrimination: Applications to Medicinal Chemistry and Drug Studies. Wiley. p. 17. ISBN 978-0-470-43352-2. Retrieved 2 November 2024.
 | This neuroscience article is a stub. You can help Wikipedia by expanding it. |